Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Wegener · SciRah

Researcher profile · Semantic Scholar

W. Wegener

Share profile

W. Wegener — researcher profile on SciRah

h-index: 40
Works: 172
Citations: 6,853

Most-cited papers

Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
A. Bardia, I. Mayer, L. Vahdat, S. Tolaney +15 more
2019New England Journal of Medicine705 citations
Semantic Scholar
Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.
A. Bardia, W. Messersmith, E. Kio, J. Berlin +19 more
2021Annals of Oncology389 citations Open access
Semantic Scholar
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
A. Starodub, A. Ocean, M. Shah, M. Guarino +9 more
2015Clinical Cancer Research285 citations Open access
Semantic Scholar
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
A. Ocean, A. Starodub, A. Bardia, L. Vahdat +10 more
2017Cancer226 citations Open access
Semantic Scholar
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
A. Bardia, I. Mayer, J. Diamond, R. Moroose +18 more
2017Journal of Clinical Oncology203 citations Open access
Semantic Scholar
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
R. Heist, M. Guarino, G. Masters, W. Purcell +14 more
2017Journal of Clinical Oncology163 citations
Semantic Scholar
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
J. Gray, R. Heist, A. Starodub, D. Camidge +19 more
2017Clinical Cancer Research148 citations Open access
Semantic Scholar
Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.
K. Kalinsky, J. Diamond, L. Vahdat, S. Tolaney +12 more
2020Annals of Oncology139 citations Open access
Semantic Scholar
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
A. Bardia, I. Mayer, J. Diamond, R. Moroose +18 more
2017Journal of Clinical Oncology130 citations Open access
Semantic Scholar
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
D. Wallace, C. Gordon, V. Strand, K. Hobbs +10 more
2013Rheumatology125 citations Open access
Semantic Scholar
Phase I, multicentre, dose‐escalation trial of monotherapy with milatuzumab (humanized anti‐CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
Jonathan L. Kaufman, R. Niesvizky, Edward A. Stadtmauer, A. Chanan-Khan +4 more
2013British Journal of Haematology109 citations
Semantic Scholar
Re-induction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL): Phase II Results from Children’s Oncology Group (COG) Study ADVL04P2
E. Raetz, M. Cairo, Michael J. Borowitz, Xiao-Min Lu +9 more
2015Pediatric Blood & Cancer94 citations Open access
Semantic Scholar
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
Efrat Dotan, S. J. Cohen, A. Starodub, C. Lieu +11 more
2017Journal of Clinical Oncology88 citations Open access
Semantic Scholar
Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
S. Tagawa, B. Faltas, E. Lam, P. Saylor +10 more
2019Journal of Clinical Oncology80 citations
Semantic Scholar
Fractionated Radioimmunotherapy With 90Y-Clivatuzumab Tetraxetan and Low-Dose Gemcitabine Is Active in Advanced Pancreatic Cancer
A. Ocean, K. Pennington, M. Guarino, A. Sheikh +16 more
2012Cancer78 citations Open access
Semantic Scholar
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
V. Strand, M. Petri, K. Kalunian, C. Gordon +6 more
2013Rheumatology68 citations Open access
Semantic Scholar
Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
S. Gulec, S. J. Cohen, K. Pennington, L. Zuckier +7 more
2011Clinical Cancer Research61 citations Open access
Semantic Scholar
Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
C. Ellebrecht, E. Choi, D. Allman, D. Tsai +3 more
2014JAMA dermatology60 citations Open access
Semantic Scholar
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
D. Goldenberg, F. Morschhauser, W. Wegener
2010Leukemia and Lymphoma55 citations
Semantic Scholar
Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome
J. Gottenberg, T. Dörner, H. Bootsma, V. Devauchelle-Pensec +13 more
2018Arthritis & Rheumatology54 citations Open access
Semantic Scholar
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma
G. Negrea, R. Elstrom, S. Allen, K. Rai +6 more
2011Haematologica50 citations Open access
Semantic Scholar
Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany.
N. Wüppenhorst, S. Draeger, H. P. Stuger, B. Hobmaier +80 more
2014Journal of Antimicrobial Chemotherapy42 citations Open access
Semantic Scholar
Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2
E. Raetz, M. Cairo, M. Borowitz, Xiao-Min Lu +8 more
201140 citations
Semantic Scholar
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
P. Chevallier, T. Eugène, N. Robillard, F. Isnard +23 more
2015The Lancet Haematology35 citations
Semantic Scholar
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Beth Christian, Ming J. Poi, Jeffrey A. Jones, P. Porcu +10 more
2015British Journal of Haematology34 citations Open access
Semantic Scholar
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
D. Wallace, F. Figueras, W. Wegener, D. Goldenberg
2021Annals of the Rheumatic Diseases33 citations
Semantic Scholar
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.
F. Kraeber-Bodéré, A. Pallardy, H. Maisonneuve, L. Campion +26 more
2017The Lancet Haematology30 citations
Semantic Scholar
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
V. Picozzi, R. Ramanathan, M. Lowery, A. Ocean +27 more
2015European Journal of Cancer28 citations Open access
Semantic Scholar
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
T. Witzig, M. Tomblyn, J. Misleh, E. Kio +3 more
2014Haematologica28 citations Open access
Semantic Scholar
Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
H. Liebman, M. Saleh, J. Bussel, Ovidiu George Negrea +3 more
2013British Journal of Haematology26 citations Open access
Semantic Scholar
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study
P. Chevallier, F. Huguet, E. Raffoux, A. Etienne +12 more
2015Haematologica24 citations Open access
Semantic Scholar
Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma.
J. Kaufman, R. Niesvizky, Edward A. Stadtmauer, A. Chanan-Khan +5 more
2016Journal of Clinical Oncology23 citations
Semantic Scholar
Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).
A. Bardia, J. Diamond, L. Vahdat, S. Tolaney +10 more
201821 citations
Semantic Scholar
Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
A. Bardia, L. Vahdat, J. Diamond, K. Kalinsky +13 more
201820 citations
Semantic Scholar
858PSacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results
S. Tagawa, B. Faltas, E. Lam, P. Saylor +13 more
201720 citations Open access
Semantic Scholar
University of Groningen Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren's Syndrome Post Hoc Analyses From the EMBODY Trials
J. Gottenberg, H. Bootsma, S. Bowman, X. Mariette +9 more
201819 citations
Semantic Scholar
BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle
P. Chevallier, C. Bodet-Milin, N. Robillard, T. Eugène +8 more
2013European Journal of Haematology15 citations
Semantic Scholar
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*
M. Kalaycio, O. George Negrea, S. Allen, K. Rai +4 more
2016Leukemia and Lymphoma13 citations
Semantic Scholar
Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
A. Bardia, L. Vahdat, J. Diamond, A. Starodub +12 more
201512 citations
Semantic Scholar
Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies
N. Segal, Efrat Dotan, J. Berlin, A. Starodub +7 more
201412 citations
Semantic Scholar
Abstract PD3-06: Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
A. Bardia, J. Diamond, I. Mayer, A. Starodub +20 more
201611 citations
Semantic Scholar
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.
Efrat Dotan, A. Starodub, J. Berlin, C. Lieu +9 more
201511 citations
Semantic Scholar
CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE)
D. Wallace, W. Wegener, H. Horne, D. Goldenberg
2016Lupus Science and Medicine10 citations
Semantic Scholar
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
H. A. Liebman, M. Saleh, J. Bussel, O. George Negrea +3 more
2016Haematologica9 citations Open access
Semantic Scholar
Abstract LB-159: A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC).
N. Segal, J. Verghis, S. Govindan, P. Maliakal +4 more
20139 citations
Semantic Scholar
Feasibility and results of a randomized phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.
V. Picozzi, R. Ramanathan, M. Lowery, A. Ocean +16 more
20148 citations
Semantic Scholar
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia
P. Chevallier, S. Chantepie, F. Huguet, E. Raffoux +17 more
2017Haematologica7 citations Open access
Semantic Scholar
Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.
A. Starodub, A. Ocean, W. Messersmith, V. Picozzi +10 more
20157 citations
Semantic Scholar
Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies
D. Stephens, A. Starodub, J. Byrd, H. Horne +3 more
20157 citations
Semantic Scholar
Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.
A. Starodub, A. Ocean, W. Messersmith, V. Picozzi +10 more
20157 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Goldenberg×38
Invite
D. Goldenberg — researcher profile on SciRah
R. Sharkey×23
Invite
R. Sharkey — researcher profile on SciRah
A. Starodub×17
Invite
A. Starodub — researcher profile on SciRah
P. Maliakal×16
Invite
P. Maliakal — researcher profile on SciRah

×16

Invite

M. Guarino — researcher profile on SciRah

Invite

A. Bardia — researcher profile on SciRah

Invite

A. Ocean — researcher profile on SciRah

Invite

L. Vahdat — researcher profile on SciRah

W. Messersmith×11

Invite

W. Messersmith — researcher profile on SciRah

S. Govindan×11

Invite

S. Govindan — researcher profile on SciRah

Invite

H. Horne — researcher profile on SciRah

K. Kalinsky×10

Invite

K. Kalinsky — researcher profile on SciRah